Compare CVS Health Corp (CVS) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Invesco Ltd. — how do they compare? CVS Health Corp trades at $93.84 (market cap $119.58B), while Invesco Ltd. trades at $31.21 (market cap $13.85B). The key difference: CVS Health Corp is far larger — about 8.6× Invesco Ltd.'s market cap, and CVS Health Corp pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| CVS | IVZ | |
|---|---|---|
Market Cap | $119.58B | $13.85B |
Sector | Health | Financials |
52-Week High | $110.60 | $32.01 |
52-Week Low | $65.51 | $20.67 |
Enterprise Value | $181.93B | $24.01B |
Dividend Yield | 2.84% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.67, down slightly by 0.03% today. The stock shows strong fundamental momentum with recent quarterly earnings beats, including Q2 2026 EPS of $2.58 versus $1.87 expected, and raised 2026 guidance. Valuation metrics appear reasonable with a P/E of 24.67 and P/S of 0.29. Technical indicators are mixed with a bullish overall signal but bearish moving averages, with key support at $95 and resistance at $96.
The outlook for CVS is positive, supported by earnings strength and analyst consensus, but risks include margin pressure and rising debt levels. The consensus price target of $115.90 implies significant upside, though investors should monitor execution on guidance and healthcare regulatory changes.
Invesco (IVZ) trades at $31.74, near its 52-week high, with a bullish technical signal supported by moving averages. The company reported mixed quarterly earnings but maintains strong operating cash flow of $1.53 billion for 2025. Recent news highlights record assets under management and positive analyst coverage, though profitability metrics show net income margin at -0.93%.
The outlook remains cautiously optimistic with a consensus price target of $32.50, offering modest upside. Key risks include volatile earnings and expense pressures, while institutional interest and dividend payments provide support. Investors should weigh solid cash generation against margin challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
